The cells of solid tumours are known to have an altered metabolism, with high rates of glucose uptake and glycolysis, which results in the excessive production of lactate. To date there has been no definitive research documenting metabolic changes in acute lymphoblastic leukaemia (ALL) cells. In order to investigate whether ALL cells have an altered metabolism, we initially compared the transcriptional profiles of 22 specimens from paediatric patients diagnosed with ALL to five CD34 þ specimens isolated from bone marrow, which was verified in an independent cohort of 101 specimens. Profiling revealed the upregulation of genes facilitating glycolysis in the ALL specimens compared to the CD34 þ specimens, while those involved in the tricarboxylic acid cycle were downregulated. Functional studies supported the microarray findings threefold: (1) higher expression of the glucose transport protein glucose transporter 1 in ALL compared to CD34 þ specimens, (2) the excessive production of lactate in ALL cell lines and (3) sensitivity of ALL cell lines to the glycolysis inhibitor 2-deoxy-D-glucose. While metabolic alterations have been well documented in solid tumours, this is the first study to provide direct evidence for the existence of metabolic changes in the leukaemic cells of ALL patients. The finding offers new options for targeted therapy for ALL patients.
Introduction
It is widely accepted that solid tumour cells have an altered metabolic profile. First described by Otto Warburg in 1956, 1 the cells of solid tumours have been shown to have elevated rates of glucose transport and glycolysis compared to their nonmalignant counterparts. This increase in glycolysis results in the production of copious amounts of lactate, even in the presence of oxygen as the result of reduced tricarboxylic acid (TCA) cycle function. 2 Although these changes have been extensively studied in solid tumours, to date there has been no definitive research documenting metabolic changes in acute lymphoblastic leukaemia (ALL). Abnormal glucose metabolism in ALL has been assumed to occur but direct evidence at the molecular level has been lacking. The current study is the first that specifically aims to identify metabolic alterations in the leukaemic cells of ALL patients and the genes that facilitate these changes.
In order to identify whether ALL cells have an altered metabolic profile we used high-density oligonucleotide microarrays. By comparing the gene expression profiles of ALL patient specimens with nonmalignant CD34 þ cells isolated from normal bone marrow we show evidence for the upregulation of glycolysis as well as the concurrent downregulation of the TCA cycle in ALL cells. Moreover, we functionally demonstrate that ALL cells have higher levels of glucose transporter 1 (GLUT1) expression than CD34 þ cells, produce high levels of lactate and are sensitive to the glycolysis inhibitor 2-deoxy-Dglucose (2DG), providing the first empirical evidence that ALL cells have a metabolic profile similar to that of solid tumours.
Materials and methods

Specimens and cell lines
Specimens were obtained from patients diagnosed and treated for B-precursor (pre-B) ALL at the Princess Margaret Hospital, Perth, Western Australia. All patients received therapy according to Children's Cancer Group (CCG) protocols. 3 In total, 22 bone marrow (BM) specimens were obtained from 11 patients, both at the time of diagnosis and when the patient relapsed. Control cells for this study were obtained from five healthy individuals who donated BM for transplants, but were not required for therapy. White blood cells (WBCs) were separated from whole BM specimens using a Lymphoprep gradient (Nycomed, Oslo, Norway) according to the manufacturer's instructions. The study was approved by the Institutional Review Board, and informed consent was obtained from all donors of specimens.
Cell lines PER-427 and PER-255 were established from ALL primary patient material from the Princess Margaret Hospital, Perth, Western Australia and were grown and maintained as previously described. 4 The microarray data for these cell lines was obtained using the same methodology described for patient specimens, see below.
Separation of CD34
þ bone marrow cells
WBCs were washed with ice-cold phosphate buffered saline (PBS) before being resuspended in PBS containing 10 mg/ml DNase. CD34 þ cells were separated from total WBCs by incubation with mouse anti-human CD34 antibody (BD Biosciences, San Jose, CA, USA) and followed by sheep antimouse IgG Dynabeads M-450 (Dynal, Oslo, Norway) in accordance with the manufacturer's instructions. CD34 þ cells were isolated with a magnet before the addition of PR34 þ stem cell releasing agent (Nexell, Irvine, CA, USA), according to the manufacturer's instructions. The separated cells were washed twice in PBS and counted before RNA was extracted. The yield of CD34 þ cells was 1-2% of total WBCs in the five normal BM specimens.
RNA isolation
Total RNA was extracted from cells using a modified TRIZOL method. 5 Briefly, cells were pelleted and washed twice with icecold PBS before being resuspended in TRIZOL reagent (Invitrogen, Carlsbad, CA, USA). After the addition of chloroform the RNA was applied to a column and washed using an RNeasy Mini kit (Qiagen, Valencia, CA, USA). The RNA was then recovered through ethanol precipitation, before being resuspended in RNase-free water. All RNA preparations were accurately quantitated and the quality assessed using an Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA).
Oligonucleotide microarrays
For hybridisation to the HG-U133A microarrays (Affymetrix, Santa Clara, CA, USA) cRNA was prepared following an adapted Affymetrix protocol, which uses 2 mg of starting RNA as previously described. 5 In brief, RNA was reverse transcribed into double-stranded DNA and the entire resulting cDNA preparation used to synthesise biotinylated cRNA, using a Bioarray High Yield RNA Transcript Labelling Kit (Enzo Life Sciences, Farmingdale, NY, USA). Biotinylated cRNA was fragmented and hybridised to the microarray, then washed and stained before scanning (GeneArray Scanner, Agilent Technologies) in accordance with Affymetrix protocols.
Quality control and consistency of results
Total RNA used for microarray experiments was of high quality, showing a 28S/18S ratio greater than 1.5 and only minor degradation as determined by the Agilent Bioanalyzer. All scanned images of microarrays met stringent quality control standards, having scaling factors of less than 20, noise values below three and the 3 0 -5 0 signal ratios of the housekeeping genes b-actin (ACTB) and glyceraldehyde-3-phosphate dehydrogenase were less than three for all microarrays.
Microarray analysis
Expression data were analysed with the program R1.7.1 (www. r-project.org) using the 'Methods for Affymetrix Oligonucleotide Arrays' package, 6 which is available from www.bioconductor. org. All microarray data generated in this study were normalised using Robust Multi-array Analysis (RMA). 7 To determine the probe sets that were expressed at a similar level in the paired ALL patient specimens, but differentially expressed to the CD34 þ control specimens, 11 two-sample t-tests were conducted for each probe set, comparing each of the paired samples in turn with the CD34 þ specimens. The t-test scores for the 11 paired specimens were then averaged to give a mean score which indicated the extent of differential gene expression between CD34
þ and ALL specimens. All probe sets were then ranked according to this score. The top 100 upregulated and downregulated probe sets in the ALL specimens were selected for further analysis.
In a second analysis, publicly available expression data on specimens from a cohort of independent paediatric ALL specimens 8 were compared with the original five CD34 þ specimens in a permutation test, chosen as it allows for the calculation of a distribution free P-value. The cel files for the 132 independent specimens were imported (www.stjuderesearch.org/data/ALL3/ rawFiles.html) and quantile normalised to our own microarray data via RMA. We used data for 101 of these pre-B ALL specimens, excluding T-ALL specimens and those with an MLL translocation (the latter measure designed to exclude the majority of infant ALL specimens as specific information regarding patient age was not available). For each probe set, a permutation test with 9999 permutations between the CD34 þ and ALL specimens was performed. The number of probe sets from the original gene expression profile of 200 probe sets significantly deregulated (Pp0.01) in the independent data set was then determined.
To verify that the five CD34 þ specimens used in our analysis displayed a pattern of expression typical of CD34 þ cells, an unsupervised hierarchical clustering was performed using data from two independent CD34 þ specimens, previously reported (Gene Expression Atlas, Genomics Institute of the Novartis Research Foundation, San Diego, CA, USA). 9 The two independent microarrays were conducted using CD34 þ bone marrow cells pooled from 33 and 19 individuals, respectively, and the cel files for these microarrays were quantile normalised to our own data, as described above. The top 200 probe sets (100 upand downregulated probe sets), were used in an unsupervised hierarchical clustering performed on the seven CD34 þ specimens (five original CD34 þ specimens in this study and two independent specimens) and the 22 pre-B ALL specimens.
Bioinformatics
The top 200 probe sets were classified according to their biological process using the Affymetrix Gene Ontology (GO) Mining Tool (www.affymetrix.com). As oligonucleotide microarrays often have more than one probe set representing a particular gene, the 200 probe sets corresponded to 179 individual genes. Of the 200 probe sets, 77 of the upregulated and 75 of the downregulated probe sets had an annotated biological process. Additionally, some probe sets were represented in more than one category. Nodes were considered significantly over-represented in the top 200 probe sets if the P-value was p0.05, as calculated using the w 2 test. Genes involved in glycolysis and the TCA cycle were cited from Biocarta pathways (www.biocarta.com). Carbohydrate transport and gluconeogenesis genes were compiled from the literature. In all cases subunits and isoforms of enzymes were included where there was a corresponding microarray probe. An averaged expression value was calculated for those genes represented by multiple probe sets. The mean expression across the 22 ALL and five CD34 þ specimens was then calculated for each gene and a two sample Student's t-test conducted to determine significance.
Western blot analysis
Whole-cell extracts were prepared as previously described. 10 Western blotting was performed with 50 mg of whole-cell extract by 10% sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) before transfer to a Hybond-C Super membrane (AP Biotech, Little Chalfont, UK). Membranes were blocked at room temperature in 5% skim milk for 1 h and incubated with either a polyclonal rabbit anti-GLUT1 antibody (MYM, Chemicon International, Temecula, CA, USA) or a rabbit IgG antiserum isotype control (sc-2027, Santa Cruz Biotechnology, Santa Cruz, CA, USA) overnight at 41C. To control for loading, the blots were also probed with pan-actin antiserum (ACTN05, Lab Vision, Fremont, CA, USA). The membranes were incubated with horseradish peroxidase (HRP)-conjugated secondary antibodies for 1 h at room temperature before visualisation of bands by enhanced chemiluminescence (Amersham Biosciences, Uppsala, Sweden). Images of the Western blots were scanned and the level of expression determined using the program Image Gauge V4.22 (Fuji Photo Film Co., Tokyo, Japan).
Glucose and lactate assays
Cells in exponential growth phase were counted by Trypan blue exclusion and seeded in 24-well plates in fresh media at 1 Â 10 6 cells per well/ml. Control wells contained no cells. Samples of culture medium were collected at 0, 24 and 48 h and diluted 100-fold. Thirty microlitre of diluted medium was used to measure glucose levels using the Amplex Red Glucose/Glucose Oxidase kit (Invitrogen), in accordance with the manufacturer's instructions. To measure lactate production 20 ml of diluted medium was used and the assay performed as described above, with lactate oxidase (Sigma, St Louis, Missouri, CA, USA) substituted for glucose oxidase.
Metabolic inhibitor assays
Cells were prepared as for the glucose and lactate assays and seeded in 96-well plates in fresh media at 1 Â 10 5 /well/100 ml. Media contained 1 mg/ml of oligomycin (Sigma) or 20 mM of 2DG (Sigma) or no additive. Cell growth was determined using a 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay. 11 Ten microlitre of MTT (5 mg/ml) was added to wells at 24 h and incubated for 6 h. After incubation 100 ml of acidified isopropyl alcohol solution was then added to dissolve formazan crystals and the absorbance measured at 590 nm. Inhibitor dosage was selected as the concentration that has been shown to reduce the relevant metabolic pathway by at least 80%.
12,13
Results
Evaluation of the gene expression profiles
The initial investigation was designed to verify whether the microarray data set obtained in this study was representative of the transcriptome of paediatric ALL and CD34 þ BM cells. First, genes expressed at a similar level between each of the paired diagnosis and relapse specimens from 11 ALL patients, but differentially expressed compared to the five CD34 þ specimens were determined, and the top 100 upregulated and top 100 downregulated probe sets identified (see Materials and methods). A similar analysis was then conducted using 101 independent ALL specimens 8 and our five CD34 þ specimens. On statistical grounds, it would be expected that by chance 1% of the genes identified in the original analysis would be significantly deregulated (Pp0.01) in an independent data set. However, over 90% of the probe sets from the original analysis were significantly deregulated (Pp0.01) in the independent data set. The extent of the overlap between the original and independent cohorts clearly indicated that the ALL specimens of this study accurately represent the gene expression profile of pre-B ALL.
The transcriptional profiles of our five CD34 þ specimens were assessed with previously published microarray data from two independent CD34 þ bone marrow cell pools. 9 The 200 top probe sets, identified as described above, were applied in an unsupervised hierarchical clustering of our five original and the two independent CD34 þ specimens as well as the 22 ALL specimens used in the original analysis. As expected the CD34 þ and ALL specimens formed distinct clusters; the analysis also showed that all seven CD34 þ specimens clustered together (Supplementary Figure S1) . This verified that the pattern of gene expression displayed by the five CD34 þ specimens from this study is equivalent to independent specimens of the same cell type analysed by others.
Evidence of metabolic alterations in the ALL gene expression profile
To ascertain whether there were metabolic differences between ALL and the nonmalignant CD34 þ control population, we first examined the top 100 upregulated and top 100 downregulated probe sets identified as differentially expressed. These top 200 probe sets in the ALL specimens equated to 179 individual genes (see Supplementary Table S1 ). The upregulated genes with the highest fold-change in the ALL specimens were the growth factor CTGF (19.4-fold) and the LIM domain protein CSRP2 (13.0-fold). Both these genes are involved in growth-related pathways and so their elevated expression is not unexpected. The homeobox gene HOXA9, a gene involved in myeloid cell proliferation and differentiation, was the most downregulated gene in the ALL specimens (23.2-fold). Other genes strongly downregulated were the carboxypeptidase CPA3 (16.3-fold) and the mast cell receptor FCER1A (17.41-fold).
A GO analysis was then conducted to obtain an overview of the function of the differentially expressed genes. This analysis on the top 200 probe sets revealed that the GO group of lipid metabolism was significantly over-represented in the downregulated genes, compared to the representation of genes with this classification on the entire microarray (Po0.01). This group included genes coding for enzymes involved in the breakdown of triglycerides (MGLL), the activation of fatty acids for entry into the b-oxidation pathway (SLC27A2) and the biosynthesis of long chain fatty acids (NANS).
The downregulation of genes involved in fatty acid synthesis and metabolism indicated that there might be a concurrent downregulation of the TCA cycle, as its function is pertinent to these processes. To investigate more closely the metabolic differences in the ALL specimens, the microarray expression levels for all major enzymes (isoforms and subunits) involved in glucose transport, glycolysis and the TCA cycle were examined (Supplementary Table S2 ; see Materials and methods). This comprehensive investigation revealed that the glucose transport genes GLUT1 and GLUT4, the monocarboxylic acid transporter SLC16A2 and the phosphofructokinase subunit PFKL, were significantly upregulated (Pp0.05) in the ALL specimens compared to the CD34 þ specimens (Figure 1 ). In addition, three of the four components of the pyruvate dehydrogenase (PDH) multienzyme complex (PDHB, DLAT, DLD) and many enzymes of the TCA cycle (IDH3B, SUCLA2, SDHC, FH, MDH1, MDH2) were significantly downregulated (Pp0.05). The lactate dehydrogenase isoform LDHB, which converts lactate into pyruvate, was identified as part of the top 200 probe sets.
High GLUT1 mRNA expression correlates with increased glucose consumption
Our findings on genes involved in glycolysis and the TCA cycle suggested that in ALL the rate of glycolysis might be increased while at the same time respiration, through the TCA cycle, might be decreased (Figure 2 ). This is a well-know phenomenon of solid tumours that results in the production of large amounts of lactate from these cells.
To ensure that differences in microarray mRNA expression correlated with protein expression we first examined the expression of GLUT1 by immunoblot using total protein extracted from two ALL and two CD34 þ specimens. Limited numbers of ALL patient and CD34 þ specimens were analysed due to the availability of material. GLUT1 migrates on an SDS-PAGE gel as a broad band of between 50-70 kDa, due to the presence of N-linked glycosylation.
14 In leukaemia cells the presence of lower molecular weight bands of between 30 and 40 kDa has also been reported. 15 Relative to ACTB the ALL patient specimens had a higher expression of GLUT1 in comparison to the CD34 þ specimens (Figure 3a and b) . The majority of total GLUT1 protein in the ALL specimens was expressed in the 50-70 kDa form, while in the CD34 þ specimens the majority of GLUT1 was expressed in the lower molecular weight forms (Figure 3a) . The level of GLUT1 expression in the specimens measured by Western blot was very similar to the expression predicted by microarray (Figure 3b) .
In order to verify that the ALL cells had the metabolic defect we analysed the rate of glucose consumption and lactate production of two ALL cell lines. Cell lines were used for these experiments, as primary patient cells placed in culture are subject to significant stress and thus are unlikely to give a true indication of metabolic activity (in vivo). Glucose consumption and lactate production were determined for both cell lines by measuring glucose and lactate levels in culture media at 0, 24 and 48 h (as described in the Materials and methods). Metabolite consumption and production were then calculated for 24 and 48 h of culture. The cell line PER-427 had a higher rate of glucose utilisation and produced a higher amount of lactate than PER-255, at both time points (Figure 3c ). PER-427 also had a two-fold higher expression of GLUT1 than PER-255 as assessed by microarray. The ratio of lactate production to glucose consumption was then calculated to determine whether the cell lines were glycolytic. In the presence of oxygen cells completely oxidise glucose to carbon dioxide and water through the TCA cycle and oxidative phosphorylation, however, under anaerobic conditions each molecule of glucose is converted to two molecules of lactate. Therefore, under aerobic conditions normal cells would have a lactate production to glucose consumption ratio (LP:GC) close to zero, while under anaerobic conditions and therefore without the use of the TCA cycle and oxidative phosphorylation, cells would have a LP:GC of close to two. The cell line PER-427, which expresses GLUT1 at high levels, appeared to be glycolytic in the presence of oxygen with a LP:GC of 1.4 (70.29), averaged over three separate experiments. A similar ratio (LP:GC ¼ 1.3) was obtained for the T-ALL cell line Jurkat using data recently published. 16 Notably these data were obtained using a different method, 13 C-nuclear magnetic resonance spectroscopy. These values are also similar to the ratio determined in breast cancer tissue (LP:GC ¼ 1.8). 17 In contrast, the lower GLUT1 expressing cell line examined in this study, PER-255, had a LP:GC of 0.7 (70.40).
The Western blot analysis of GLUT1 expression confirmed that ALL cells have increased glucose transporter expression in comparison to normal CD34 þ BM cells. Additionally, the metabolic studies in ALL cell lines functionally verified the glycolytic status of ALL cells. To further substantiate that ALL cells utilise glycolysis under aerobic conditions we used the metabolic inhibitors oligomycin and 2DG. Oligomycin inhibits the adenosine 5 0 triphosphate (ATP) synthase complex blocking ATP production, functionally inhibiting TCA cycle and oxidative phosphorylation, while the glucose analogue 2DG is metabolized to a compound that blocks glycolysis. As shown in Figure 3d , treatment with oligomycin had a minimal effect on cell growth, however, treatment with 2DG resulted in growth 
Discussion
Based on an observation made 50 years ago, solid tumour cells are known to have altered glucose metabolism, resulting in the production of lactate at high levels. 1 The current study provides evidence for the occurrence of similar changes in glucose metabolism in the leukaemic cells of ALL patients. Although abnormalities in cellular metabolism have been indirectly observed in leukaemic cell lines 15, 16, 19 and to a lesser extent clinically, 20 there has been no specific documentation of the genes involved in these processes in ALL cells.
An investigation of the gene expression levels of glucose transporter, glycolysis and TCA cycle genes in 22 ALL patient specimens compared to five normal CD34 þ BM specimens, revealed a pattern of deregulation in keeping with the known metabolic changes that occur in solid tumours. These findings were outside of our initial lists of top-ranked genes, indicating that although these genes may be important, not all processes occurring in the cell can be captured through this method of analysis. Investigation into the roles of the top-ranked genes is ongoing. The upregulation of genes coding for glucose transport proteins (GLUT1, GLUT4) allows a cell to increase the rate of glycolysis by enhancing glucose uptake (Figure 2) . A ratelimiting step in glycolysis controlled by PFK may be passed via the upregulation of PFKL, as this particular subunit of PFK is less sensitive to inhibition by citrate and ATP. 21, 22 Further to this, many genes that code for TCA cycle enzymes were downregulated including three of the four subunits of the PDH complex, which catalyses the conversion of pyruvate to acetylCoA and is an essential step for most products entering the TCA cycle. The upregulation of the monocarboxylic transporter SLC16A2 provides a means for the cell to expel the excess lactate produced through the elevated glycolytic and decreased TCA cycle activity (Figure 2) .
In order to validate the findings from mRNA expression, several biochemical investigations were conducted. Three lines of evidence support our microarray results. Firstly, differences observed in GLUT1 mRNA expression by microarray correlated with differences in protein expression in the ALL patient and CD34 þ BM specimens. Additionally, the ALL specimens had a greater level of N-glycosylation (50-70kDa) of GLUT1 than the CD34 þ specimens, which is thought to increase the transporters affinity for glucose. 14, 15 Secondly, these cells produced lactate in the presence of oxygen, although these levels varied between cell lines, and future studies should address the degree of heterogeneity in primary leukaemia specimens. Thirdly, the growth of ALL cell lines is affected by the glycolysis inhibitor 2DG but not the TCA cycle/oxidative phosphorylation inhibitor oligomycin, suggesting that the TCA cycle and oxidative phosphorylation is not the major pathway for energy generation in ALL cells and that there is more reliance on glycolysis. The initial microarray and protein measurements in this study were conducted using primary patient material, and while it must be noted that functional studies were conducted in ALL cell lines, not primary specimens, the results strongly indicate that ALL cells have a similar metabolic profile to solid tumour cells.
Why cancer cells adopt glycolysis as a means of producing energy is still unclear. Originally thought to be a function of limited oxygen supply in the core of solid tumours, the theory is now beginning to emerge that these metabolic changes are essential for transformed cells, providing an important survival advantage. 23 Hypoxia-inducible transcription factor 1 (HIF-1) plays a key role in augmenting glycolysis in response to oxygen levels, 24 but there is mounting evidence that the primary genetic lesions facilitate the shift to aerobic glycolysis observed in cancer cells. Oncogenes MYC and RAS have been shown to have a role in increasing glucose uptake and glycolysis. [25] [26] [27] [28] Further to this, there is evidence for a signalling pathway which links reduced succinate dehydrogenase (SDH) expression with tumour progression through HIF-1. 29 Reduced expression of SDH and other TCA cycle intermediates through mutations, loss of heterozygosity or downregulation of expression has been reported in colorectal and gastric cancers, 30 and this may provide another means for these cancer cells to gain metabolic advantages. High levels of HIF1A, VEGF and the VEGF receptor expression have previously been observed in ALL cells. 31 In concordance with these results we found two of three genes coding for HIFs (HIF2A, HIF3A) and the VEGF receptor VEGFR1 significantly upregulated in the ALL specimens compared to CD34 þ specimens (Po0.05). In order to determine what pathways are responsible for the observed metabolic changes in ALL cells further research needs to be conducted.
These observed metabolic changes might not only be linked to tumourigenesis but also disease progression and clinical outcome. Microarray studies of drug resistance in ALL revealed that genes involved in carbohydrate and protein metabolism might be related to drug sensitivity 32, 33 and hence, treatment response and prognosis. A recent finding reported by Xu et al. 18 highlights the potential use of glycolysis inhibitors in ALL treatment. The study assessed the efficacy of two drugs that target distinct pathways, 3-bromo-2-oxopropionate-1-propyl and rapamycin, inhibitors of the glycolysis and mammalian target of rapamycin pathways, respectively. Individually, these drugs had a minimal effect on the growth of cells in vitro, however, when used concurrently these drugs promoted cell death and almost completely inhibited cellular proliferation in leukaemia and lymphoma cell lines. The findings reported in the current study provide evidence that the leukaemic cells of ALL patients have the metabolic profile that confers a growth advantage in vivo, while the report by Xu et al. 18 strongly suggests that these observed metabolic changes may be exploited in therapy. Metabolic pathways and their regulation may be intimately linked to cell transformation, disease progression and response to treatment in ALL, as well as in many other cancers, and is an exciting avenue for the development of new therapeutics in the near future.
